Monika Vyas

Monika Vyas

Auto-generated profile, based on publicly available information

Monika Vyas

Department of Pathology Beth Israel Deaconess Medical Center Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2016 in Cancer
Verified
Journal Article
Open access
PDF file
MPManju L. Prasad
Manju L. Prasad
MVMonika Vyas
Monika Vyas
MHMatthew J. Horne
Matthew J. Horne
RVRenu K. Virk
Renu K. Virk
RMRaffaella Morotti
Raffaella Morotti
YNYuri E. Nikiforov
Yuri E. Nikiforov
BACKGROUND: An increase in thyroid cancers, predominantly papillary thyroid carcinoma (PTC), has been recently reported in children.METHODS: The histopathology of 28 consecutive PTCs from the northeast United States was reviewed. None of the patients (ages 6‐18 years; 20 females, 8 males) had significant exposure to radiation. Nucleic acid from tumors was tested for genetic abnormalities (n = 27). Negative results were reevaluated by targeted next‐generation sequencing.RESULTS: Seven of 27 PTCs (26%) had neurotrophic tyrosine kinase receptor (NTRK) fusion oncogenes (NTRK type 3/ets variant 6 [NTRK3/ETV6], n =5; NTRK3/unknown, n = 1; and NTRK type 1/translocated promoter region, nuclear basket protein [NTRK1/TPR], n = 1), including 5 tumors that measured >2 cm and 3 that diffusely involved the entire thyroid or lobe. All 7 tumors had lymphatic invasion, and 5 had vascular invasion. Six of 27 PTCs (22%) had ret proto‐oncogene (RET) fusions (RET/PTC1, n = 5; RET/PTC3, n = 1); 2 tumors measured >2 cm and diffusely involved the thyroid, and 5 had lymphatic invasion, with vascular invasion in 2. Thirteen PTCs had the B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) valine‐to‐glutamic acid mutation at position 600 (BRAFV600E) (13 of 27 tumors; 48%), 11 measured <2 cm, and 6 had lymphatic invasion (46%), with vascular invasion in 3. Fusion oncogene tumors, compared with BRAFV600E PTCs, were associated with large size (mean, 2.2 cm vs 1.5 cm, respectively; P = .05), solid and diffuse variants (11 of 13 vs 0 of 13 tumors, respectively; P < .001), and lymphovascular invasion (12 of 13 vs 6 of 13 tumors, respectively; P = .02); BRAFV600E PTCs were predominantly the classic variant (12 of 13 vs 1 of 13 tumors). Two tumors metastasized to the lung, and both had fusion oncogenes (NTRK1/TPR, n = 1; RET/PTC1, n = 1).CONCLUSIONS: Fusion oncogene PTC presents with more extensive disease and aggressive pathology than BRAFV600E PTC in the pediatric population. The high prevalence of the NTRK1/NTRK3 fusion oncogene PTCs in the United States is unusual and needs further investigation. Cancer 2016;122:1097–1107. © 2016 American Cancer Society

1 November 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
MVMonika Vyas
Monika Vyas
JHJaclyn F. Hechtman
Jaclyn F. Hechtman
YZYanming Zhang
Yanming Zhang
RBRyma Benayed
Ryma Benayed
AYAslihan Yavas
Aslihan Yavas
Olca BasturkOlca Basturk
Olca Basturk

1 August 2014 in Human Pathology
Verified
Journal Article
Closed access
RMRyan A. Metcalf
Ryan A. Metcalf
AMAhmad Monabati
Ahmad Monabati
MVMonika Vyas
Monika Vyas
CACNIO/ Unidad Anticuerpos
CNIO/ Unidad Anticuerpos
GGGabriela Gualco
Gabriela Gualco
AFAharon G. Freud
Aharon G. Freud

1 January 2019 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
SLSandy Liu
Sandy Liu
MGMithat Gӧnen
Mithat Gӧnen
ZSZsofia K. Stadler
Zsofia K. Stadler
MWMartin R. Weiser
Martin R. Weiser
JHJaclyn F. Hechtman
Jaclyn F. Hechtman
JSJinru Shia
Jinru Shia
Blockade of the interaction between PD-1 and its ligands PD-L1 has shown clinical efficacy across several tumor types, especially in mismatch-repair-deficient colorectal carcinoma. The aim of this study was to examine the pattern and cellular localization of PD-L1 expression in the different molecular subtypes of mismatch-repair-deficient colorectal cancers vs. their mismatch-repair-proficient counterparts. PD-L1/SATB2 double-antibody-immunohistochemistry was utilized to distinguish tumor cell from immune cell staining. We observed in our series of 129 colorectal adenocarcinomas that PD-L1 expression occurred primarily in tumor-associated-immune cells and most prominently at the tumor-stroma-interface of the invasive front. The level of invasive front immune cell staining was significantly higher in mismatch-repair-deficient tumors compared to mismatch-repair-proficient tumors (p < 0.001), but no difference was observed among the different subtypes of mismatch-repair-deficient tumors: Lynch syndrome-associated vs. MLH1-methylated vs. unexplained. While selected mismatch-repair-proficient tumors exhibited unusually high tumor-infiltrating-lymphocytes and had high level immune cell PD-L1 expression, a positive correlation between PD-L1 expression and high lymphocyte count was detected only in mismatch-repair-deficient tumors (r = 0.39, p < 0.001) and not in mismatch-repair-proficient tumors. Notably, true tumor cell PD-L1 expression in colorectal carcinoma was rare, present in only 3 of 129 tumors (2.3%): 2 MLH1-methylated and 1 mismatch-repair-proficient with high tumor-infiltrating-lymphocytes; and the staining in the tumor cells in all 3 was diffuse (>=50% of the tumor). These findings may serve to inform further efforts aiming to evaluate PD-L1 immunohistochemistry vis-à-vis molecular sub-classification as predictive biomarkers in the treatment of colorectal carcinoma.

1 August 2018 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
RJRadoslav Janostiak
Radoslav Janostiak
MVMonika Vyas
Monika Vyas
ACAli Fuat Cicek
Ali Fuat Cicek
NWNarendra Wajapeyee
Narendra Wajapeyee
MHMalini Harigopal
Malini Harigopal

20 November 2018 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ZHZishuo Ian Hu
Zishuo Ian Hu
MHMatthew D. Hellmann
Matthew D. Hellmann
JWJedd D. Wolchok
Jedd D. Wolchok
MVMonika Vyas
Monika Vyas
JSJinru Shia
Jinru Shia
Eileen O'ReillyEileen O'Reilly
Eileen O'Reilly
Background MMR-D pancreatic cancer have been reported to respond to checkpoint inhibitor therapy. Here, we report the first case of acquired resistance to immunotherapy in MMR-D pancreatic cancer. Case presentation A 45-year-old woman with unresectable MMR-D pancreatic cancer was initially treated with FOLFIRINOX, FOLFIRI, and stereotactic body radiation with stable disease burden. After 3 months, imaging showed progression of disease with an increase in CA19-9. She was subsequently enrolled in a clinical trial of an anti-PD-L1 antibody in combination with an IDO1 inhibitor. She demonstrated a partial response to therapy by RECIST 1.1 criteria with declining tumor markers. Twenty-two months after beginning immunotherapy, imaging revealed an increasing left ovarian cystic mass. There were no other sites of progressive disease. The patient underwent a total hysterectomy and bilateral salpingo-oophorectomy, appendectomy, omentectomy and pelvic lymphadenopathy. Pathology was consistent with a metastasis from the pancreas involving the endometrium and left ovary. Thereafter, the patient continued with PD-1 blockade therapy off protocol with no further progressive disease. Immune profiling showed high levels of CD8+ T cells and PD-1 positive immune cells infiltrating the tumor, with a moderate level of PD-L1 expression in both the immune cells and the tumor cells. Next generation sequencing found only the KRAS G12D and RNF43 G659Vfs*41 mutations were retained from the pre-treatment tumor in the treatment-resistant tumor. Conclusions This is the first report describing acquired resistance to immunotherapy in MMR-D pancreatic cancer with accompanying genomic and immune profiling. This case of oligoprogression in the setting of immunotherapy demonstrates the feasibility of localized treatment followed by continuation of immunotherapy to sustain ongoing response.